Rimini, Margherita
Masi, Gianluca
Lonardi, Sara
Nichetti, Federico
Pressiani, Tiziana
Lavacchi, Daniele
Jessica, Lucchetti
Giordano, Guido
Scartozzi, Mario
Tamburini, Emiliano
Pastorino, Alessandro
Rapposelli, Ilario Giovanni
Daniele, Bruno
Martinelli, Erika
Garajova, Ingrid
Aprile, Giuseppe
Schirripa, Marta
Formica, Vincenzo
Salani, Francesca
Winchler, Costanza
Bergamo, Francesca
Balsano, Rita
Gusmaroli, Eleonora
Lorenzo, Angotti
Landriscina, Matteo
Pretta, Andrea
Toma, Ilaria
Pirrone, Chiara
Diana, Anna
Leone, Francesco
Brunetti, Oronzo
Brandi, Giovanni
Garattini, Silvio Ken
Satolli, Maria Antonietta
Rossari, Federico
Fornaro, Lorenzo
Niger, Monica
Zanuso, Valentina
De Rosa, Antonio
Ratti, Francesca
Aldrighetti, Luca
De Braud, Filippo
Foti, Silvia
Rizzato, Mario Domenico
Vivaldi, Caterina
Stefano, Cascinu
Rimassa, Lorenza
Antonuzzo, Lorenzo
Casadei-Gardini, Andrea https://orcid.org/0000-0001-6289-7202
Article History
Accepted: 2 April 2024
First Online: 1 May 2024
Declarations
:
: No external funding was used in the preparation of this manuscript.
: L.R. reports consulting fees from AbbVie, AstraZeneca, Basilea, Bayer, BMS, Eisai, Elevar Therapeutics, Exelixis, Genenta, Hengrui, Incyte, Ipsen, IQVIA, Jazz Pharmaceuticals, MSD, Nerviano Medical Sciences, Roche, Servier, Taiho Oncology, and Zymeworks; lecture fees from AstraZeneca, Bayer, BMS, Eisai, Incyte, Ipsen, Merck Serono, Roche, and Servier; travel expenses from AstraZeneca; research grants (to institution) from Agios, AstraZeneca, BeiGene, Eisai, Exelixis, Fibrogen, Incyte, Ipsen, Lilly, MSD, Nerviano Medical Sciences, Roche, Servier, and Zymeworks. T.P. received consulting fees from Bayer, Ipsen, and AstraZeneca; institutional research funding from Roche, Bayer, and AstraZeneca; travel expenses from Roche. A.C.G. reports consulting fees from AstraZeneca, Bayer, BMS, Eisai, Incyte, Ipsen, IQVIA, MSD, Roche, and Servier; lecture fees from AstraZeneca, Bayer, BMS, Eisai, Incyte, Ipsen, Roche, and Servier; travel expenses from AstraZeneca; research grants (to institution) from AstraZeneca and Eisai. Margherita Rimini, Gianluca Masi, Sara Lonardi, Federico Nichetti, Daniele Lavacchi, Lucchetti Jessica, Guido Giordano, Mario Scartozzi, Emiliano Tamburini, Alessandro Pastorino, Ilario Giovanni Rapposelli, Bruno Daniele, Erika Martinelli, Ingrid Garajova, Giuseppe Aprile, Marta Schirripa, Vincenzo Formica, Francesca Salani, Costanza Winchler, Francesca Bergamo, Rita Balsano, Eleonora Gusmaroli, Angotti Lorenzo, Matteo Landriscina, Andrea Pretta, Ilaria Toma, Chiara Pirrone, Anna Diana, Francesco Leone, Oronzo Brunetti, Giovanni Brandi, Silvio Ken Garattini, Maria Antonietta Satolli, Federico Rossari, Lorenzo Fornaro, Monica Niger, Valentina Zanuso, Antonio De Rosa, Francesca Ratti, Luca Aldrighetti, Filippo De Braud, Silvia Foti, Mario Domenico Rizzato, Caterina Vivaldi, Cascinu Stefano, and Lorenzo Antonuzzo declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.
: The study was conducted in accordance with the Declaration of Helsinki and the protocol was approved by the ethics committee of each institution involved in the project. Under the condition of retrospective archival tissue collection and patient data anonymization, our study was exempt from the acquisition of informed consent from patients by the institutional review board.
: Not applicable.
: The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.
: Not applicable.
: Conception and design: A. Casadei-Gardini, M. Rimini, Lorenza Rimassa, Lorenzo Fornaro, Sara Lonardi, Lorenzo Antonuzzo. Acquisition of data (acquired and managed patients): All authors. Analysis and interpretation of data: A. Casadei-Gardini, M. Rimini, Lorenza Rimassa, Lorenzo Fornaro, Sara Lonardi, Lorenzo Antonuzzo. Writing, review, and/or revision of the manuscript: A. Casadei-Gardini, M. Rimini, Lorenza Rimassa, Lorenzo Fornaro, Sara Lonardi, Lorenzo Antonuzzo. Final approval of manuscript: All authors.